Showing 1 - 7 results of 7 for search 'Peter Bader', query time: 0.03s Refine Results
  1. 1
    CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma

    CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma by Laura M. Moser, Laura M. Moser, Laura M. Moser, Laura M. Moser, Laura M. Moser, Catrin Heim, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Philipp Wendel, Philipp Wendel, Philipp Wendel, Philipp Wendel, Süleyman Bozkurt, Sabine Harenkamp, Hermann Kreyenberg, Hermann Kreyenberg, Michael Merker, Michael Merker, Christian Münch, Christian Münch, Christian Münch, Elise Gradhand, Meike Vogler, Meike Vogler, Meike Vogler, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Halvard Bönig, Halvard Bönig, Jan-Henning Klusmann, Jan-Henning Klusmann, Jan-Henning Klusmann, Jan-Henning Klusmann, Peter Bader, Peter Bader, Peter Bader, Peter Bader, Peter Bader, Winfried S. Wels, Winfried S. Wels, Winfried S. Wels, Eva Rettinger, Eva Rettinger, Eva Rettinger, Eva Rettinger, Eva Rettinger

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation

    Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow tra... by Sarah Kayser, Sarah Kayser, Sarah Kayser, Emilia Salzmann-Manrique, Hubert Serve, Hubert Serve, Hubert Serve, Peter Bader, Peter Bader, Jan-Henning Klusmann, Jan-Henning Klusmann, Jan-Henning Klusmann, Christian Seidl, Joachim Schwäble, Gesine Bug, Gesine Bug, Gesine Bug, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation

    Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation by Catrin Heim, Leonie Hartig, Nadine Weinelt, Laura M. Moser, Emilia Salzmann-Manrique, Michael Merker, Winfried S. Wels, Torsten Tonn, Peter Bader, Jan-Henning Klusmann, Sjoerd J.L. van Wijk, Eva Rettinger

    Published 2024-06-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Eight induced pluripotent stem cell lines (iPSCs) derived from two patients with Leukocyte adhesion deficiency Type I (LAD I) with mutations in the ITGB2 gene

    Eight induced pluripotent stem cell lines (iPSCs) derived from two patients with Leukocyte adhesion deficiency Type I (LAD I) with mutations in the ITGB2 gene by Julia Fekadu-Siebald, Nina V Fuchs, Stella Zahn, Marcel G E Rommel, Franziska Schenk, Sabine Huenecke, Melanie Bremm, Hermann Kreyenberg, Zyrafete Kuci, Eva-Maria Jacobsen, Manfred Hoenig, Klaus Schwarz, Peter Bader, Ute Modlich, Renate König, Shahrzad Bakhtiar

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial

    Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial by Adriana Balduzzi, Evgenia Glogova, Christina Peters, Petr Sedlacek, Jean-Hugues Dalle, Franco Locatelli, Roland Meisel, Birgit Burkhardt, Jochen Buechner, Jacek Wachowiak, Marc Bierings, Raquel Staciuk, Stelios Graphakos, Tayfun Güngör, Akif Yesilipek, Peter Svec, Julia Palma, Gergely Krivan, Cristina Diaz-de-Heredia, Francesca Limido, Marc Ansari, Krzysztof Kalwak, Peter Bader, Marianne Ifversen

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Extended clinical phenotypes and treatment modalities in 32 JAGN1-deficient patients: a multicenter study by ESID and EBMT IEWP

    Extended clinical phenotypes and treatment modalities in 32 JAGN1-deficient patients: a multicenter study by ESID and EBMT IEWP by Julia Fekadu-Siebald, Emilia Salzmann-Manrique, Jan Robert Heusel, Andre Willasch, Fabian Hauck, Luis Ignacio Gonzalez-Granado, Zahra Chavoshzadeh, Samin Sharafian, Franziska Cuntz, Safa Baris, Andrea Finocchi, Mattia Algeri, Roya Sherkat, Maja Klaudel-Dreszler, Cornelia Zeidler, Christine Bellanné-Chantelot, Gerhard Kindle, Blandine Beaupain, Catherine Paillard, Markus Seidel, Peter Bader, Michael H. Albert, Bénédicte Neven, Jean Donadieu, Shahrzad Bakhtiar

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM

    Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM by Krzysztof Kalwak, Laura M. Moser, Ulrike Pötschger, Peter Bader, Katharina Kleinschmidt, Roland Meisel, Jean-Hugues Dalle, Akif Yesilipek, Adriana Balduzzi, Gergely Krivan, Evgenios Goussetis, Raquel Staciuk, Petr Sedlacek, Herbert Pichler, Peter Svec, Melissa Gabriel, Tayfun Güngör, Ernest Bilic, Jochen Buechner, Marleen Renard, Kim Vettenranta, Marianne Ifversen, Cristina Diaz-de-Heredia, Jerry Stein, Jacek Toporski, Marc Bierings, Christina Peters, Marc Ansari, Franco Locatelli

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: